Multiple Sclerosis. Demyelinating diseases of the central nervous system
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: MS patients who take Corkomine oral capsule for 3 months at a dose of 370 mg, take one a day at the beginning of the study and then take it twic
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: The study subjects must have RRMS type Ms disease They are 18 to 50 years old and EDSS (disease incapacity severity) must be less than 4 Patients who have been diagnosed with MS for at least one year Patients who do not have a specific digestive problem (gastric and duodenal ulcers, irritable bowel syndrome, indigestion) Not sensitive to curcumin They do not receive zinc or selenium supplements Antioxidant corticosteroids, such as vitamin E-A-D, have not been used for at least the past two weeks. They are not pregnant Don't be a breastfeeding woman They do not have special liver or kidney problems
Exclusion criteria
Exclusion criteria: Lack of willingness of the patient to continue cooperation patients with mental disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nitrogen in the blood urea. Timepoint: At the beginning of the study and 3 months after taking curcumin. Method of measurement: Blood urea nitrogen measurement kit.;Total oxidative status. Timepoint: Measurement of total oxidative status at the beginning of the study (before the start of the intervention) and 3 months after the start of use of curcumin capsules. Method of measurement: Total Oxidative Status Measurement Kit.;Malone Dialdehyde. Timepoint: Measurement of malondialdehyde at the beginning of the study (before the intervention) and 3 months after the start of use of curcumin capsules. Method of measurement: Malon dialdehyde Measurement Kit.;?? ???????. Timepoint: Measurement of oxygenated water at the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: Oxygenated water measurement kit.;Super Oxide Dismutase. Timepoint: Measurement of dismutase superoxide at the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: Dysmotase Super Oxide Measurement Kit.;Glutathione Revival. Timepoint: Measurement of glutathione reductase at the beginning of the study (before the start of the intervention) and 3 months after the start of the use of curcumin capsules. Method of measurement: Glutathione Revitalization Measurement Kit.;Aspartate amino transferase. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin. Method of measurement: Aspartate aminotransferase assay kit.;Alanin amino transferase. Timepoint: The beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin. Method of measurement: Alanine Amino Transfer Measurement Kit.;Blood creatinine. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curc | — |
Secondary
| Measure | Time frame |
|---|---|
| Expanded Disability Status Scale. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: questionnaire.;Fatigue Severity Scale. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of taking curcumin capsules. Method of measurement: questionnaire.;Gait disorder. Timepoint: At the beginning of the study (before the start of the intervention) and 3 months after the start of use of curcumin capsules. Method of measurement: 25 foot test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Goodarzi
Arak University of Medical Sciences
Outcome results
None listed